Naphthoquinone Compounds Targeting 3CL Protease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coronavirus infections, such as COVID-19, face challenges in effectively inhibiting the 3CL protease and reducing inflammation and autophagy, which are crucial for viral replication and disease severity.
Innovation Solution
A compound represented by Formula I, which includes various functional groups and can form complexes with phospholipids, is used to inhibit the 3CL protease, reduce inflammation, and inhibit autophagy, thereby treating coronavirus infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to inhibit 3CL protease, then viral replication is suppressed, but the effectiveness is insufficient due to high conservation and resistance development
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of naphthoquinone compounds (Formula I) with various substituent groups (R1-R6) to optimize binding affinity to 3CL protease. By systematically varying parameters such as substituent types, positions, and configurations, the invention achieves enhanced inhibition effectiveness while maintaining broad-spectrum activity against conserved viral proteases across different coronavirus strains.
2Reliability
If shikonin and related compounds are used to treat coronavirus infection, then antiviral activity is achieved through 3CL protease inhibition, but anti-inflammatory and autophagy inhibition effects are also needed to reduce disease severity
Solution Approach 1:
The patent applies universality by designing naphthoquinone compounds (Formula I) that simultaneously exhibit multiple therapeutic functions: 3CL protease inhibition (antiviral), anti-inflammatory activity, and autophagy inhibition. This multi-functional approach allows a single compound to address multiple pathogenic mechanisms of coronavirus infection, reducing disease severity through coordinated action on viral replication and host inflammatory response without requiring complex combination therapies.
3Productivity
If compounds with high antiviral activity are administered, then viral replication is effectively inhibited, but potential toxicity and side effects increase
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (R1-R6) at particular positions on the naphthoquinone core structure to enhance antiviral activity at the target site (3CL protease binding) while minimizing off-target toxicity. The strategic placement of hydrophobic, hydrophilic, and hydrogen-bonding groups optimizes local interactions with the protease active site, achieving high antiviral potency with improved safety profile compared to parent compounds like shikonin.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits 3CL protease, reduces inflammation, and suppresses autophagy, providing a therapeutic benefit in treating coronavirus infections by targeting key viral and host cell processes.
Implementation Method 1
A compound represented by Formula I, which includes various functional groups and can form complexes with phospholipids
Implementation Method 2
The compound effectively inhibits 3CL protease, reduces inflammation, and suppresses autophagy, providing a therapeutic benefit in treating coronavirus infections by targeting key viral and host cell processes
Data Source
AI summary
Described herein are compounds of Formula I:wherein R1-R6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.